Rhythm Pharmaceuticals (RYTM) Stifel 2024 Healthcare Conference summary

Company overview and disease focus

• Focuses on therapies targeting the melanocortin-4 pathway, crucial for satiety and energy expenditure regulation.

• Initial product approved in 2020 for rare genetic obesity, followed by a 2022 approval for Bardet-Biedl syndrome, now in global launch.

• Unexpected efficacy observed in patients with acquired hypothalamic injury, expanding the addressable population.

• Lead drug, setmelanotide, acts as an analog of alpha-melanocyte-stimulating hormone, functioning as hormone replacement.

Epidemiology and patient identification

• Estimated 5,000–10,000 U.S. patients with hypothalamic obesity (HO), though this may be conservative due to underdiagnosis.

• HO can result from tumors, trauma, or radiation, with many cases likely unrecognized until treatment becomes available.

• Congenital HO is clinically diagnosed, not typically identified through genetic screening.

• Early literature underestimated obesity as a disease, contributing to under-recognition of hypothalamic involvement.

Clinical data and trial updates

• Phase 2 data showed consistent response to setmelanotide in both pediatric and adult HO patients, with significant weight loss at 1, 3, and 6 months.

• French real-world data confirmed efficacy in adults, including those years post-injury, with uniform responses.

• New data from congenital HO patients prompted a Phase 3 trial amendment to include a separate congenital cohort (about 40 patients).

• The congenital HO sub-study is 90% powered to detect a 12% placebo-adjusted difference over 34 weeks.

• Approximately 25% of Phase 3 trial participants have prior GLP-1 exposure; 10% are currently on GLP-1s, but must be weight-stable and not adjust doses.